Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of long-term safety and efficacy of NNC6019-0001 in transthyretin amyloid cardiomyopathy
2022-502605-15-00Phase 2Authorised
- Sponsor
- Novo Nordisk
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of coramitug in amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by Novo Nordisk. Primary endpoint: Number of treatment emergent adverse events. Planned start May 2024; status: authorised.
02
Drugs
coramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on 2022-502605-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502605-15-00.